Renal denervation in treatment-resistant hypertension: a reappraisal

Alexandre Persu*, Yu Jin, Fadl Elmula M. Fadl Elmula, Jean Renkin, Aud Hoieggen, Sverre E. Kjeldsen, Jan A. Staessen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)

Abstract

The Symplicity HTN-1 and 2 studies proposed renal denervation (RDN) as an effective and safe approach to treat patients with resistant hypertension, and were followed by an unprecedented wave of enthusiasm. The announcement that Symplicity HTN-3 failed to meet its primary efficacy endpoint put an abrupt stop to these overoptimistic expectations. The use of a sound methodology was enough to see the typical 25-30 mmHg systolic blood pressure decrease observed after RDN melt down to
Original languageEnglish
Pages (from-to)48-52
JournalCurrent Opinion in Pharmacology
Volume21
DOIs
Publication statusPublished - Apr 2015

Cite this